ENIMMUNE CORPORATION
Update：2025/12/03
Industries
Main Industry
Biotechnology
Main Product/Service
At ENIMMUNE, our main business activity is to conduct clinical trials of new drugs, develop sales outlets, and collaborate with research-based pharmaceutical companies to facilitate the commercialization of new drugs. By forging an alliance within the ecosystem, we integrate all sources to roll out new drugs efficiently. The phased results of new drug development are also licensed to other manufacturers. In the future, we plan to introduce technology to develop innovative new drugs.
Founded Year
2014
Unified Business No.
54665910
Status
Active
Number of Employees
0
Total Paid-in
Capital
721,340,000 (NT$)
Location of Company
Taiwan
, Taipei City
Exit Status
Emerging Stock Exchange(2018)
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, MOE. Exit status refers to various situations, including emerging stock exchanges (e.g., potential exits), mergers and acquisitions (M&A), and IPOs. The overseas development countries are collected through information provided by startups themselves and the information filled in when registering for matchmaking events. Therefore, the information cannot be updated in real time. If you wish to make corrections, please email findit.tier@gmail.com. Thank you.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Enimmune Corp. is a biologics research and marketing company jointly established by Adimmune Corporation and a venture capital firm. Upholding an idea that the pharmaceutical industry is a life-saving cause, we are actively developing new drugs and sales outlets.
We cooperate with world-renowned research institutions to develop new drugs for unmet medical needs through technology transfer, which can reduce the risk of R&D failure and increase the chance of success in clinical trials. We also maintain connections with domestic medical centers with rich experience in clinical trials. To speed up the launch of new drugs in the global arena, we expect to build a clinical trial platform with experts in cross-strait laws and regulations through international cooperation programs.
We cooperate with world-renowned research institutions to develop new drugs for unmet medical needs through technology transfer, which can reduce the risk of R&D failure and increase the chance of success in clinical trials. We also maintain connections with domestic medical centers with rich experience in clinical trials. To speed up the launch of new drugs in the global arena, we expect to build a clinical trial platform with experts in cross-strait laws and regulations through international cooperation programs.
